The UK’s Competition Commission announced late last week that it has approved of the proposed buyout of laser eye company Ultralase by competitor Optimax Clinics following the argument that Ultralase would have gone out of business were it not for the acquisition.
Optimax finalized its buyout in November 2012, which involved the acquisition of 23 laser eye treatment clinics and three consultation locations throughout the UK, according to reports.
Following its merger review, the Commission found that Optimax was the only viable purchaser option for Ultralase and confirmed that Ultralase would not have survived without a buyout.
The Office of Fair Trading first referred the case to the Commission last July.
Full Content: 4-Traders
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI